The Maude Lab for Acute Lymphoblastic Leukemia Therapies focuses on developing and clinically evaluating new immunotherapies and targeted cancer therapies for children with high-risk and relapsed/refractory acute lymphoblastic
This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).
CHOP reaches a major milestone in pediatric cancer treatments, treating its 500th patient with CAR T-cell immunotherapy. This and more in our weekly research news roundup.
The purposes of this study is to examine efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloric restriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD ≥0.01%.
Shifting the paradigm to treat the toughest pediatric cancers with new cell therapies that reprogram a patient's own immune system to kill cancer cells.
